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Background: Generic utility instruments may not fully capture the impact and consequences of urinary problems.
Condition-specific preference-based measures, developed from previously validated disease-specific patient-reported
outcomes instruments, may add relevant information for economic evaluations. The aim of this study was to develop a
condition-specific preference-based measure, the Incontinence Utility Index (IUI), for valuing health states associated
with urinary problems.
Methods: A two-step process was implemented. First, an abbreviated health state classification system was developed
from the Incontinence Quality of Life Questionnaire (I-QOL) and Neurogenic Module by applying Rasch modelling,
classical psychometrical testing and expert criteria to data from two pivotal trials comprised of neurogenic detrusor
overactivity (NDO) patients. Criterion, convergent validity and concordance with the original instrument was assessed
in the abbreviated version. Then, a multi-attribute utility function (MAUF) was estimated from a representative sample
of the UK non-institutionalized adult general population. Visual analogue and time-trade off (TTO) evaluations were
applied in the elicitation process. Predictive validity of the MAUF was tested comparing estimated and direct
utility scores.
Results: The abbreviated health state classification system generated from the NDO sample contained 5 attributes
with 3 levels of response and had adequate psychometrical properties: significant differences in scores according to
the reduction in the frequency of urinary incontinence episodes [UIE] (p < 0.001); Spearman correlation coefficient with
number of daily UIE = −0.43; p < 0.01 and Intraclass Correlation Coefficient (ICC, 95% CI) with the original version = 0.90
(0.89-0.91; p < 0.001). Next, 442 participants were interviewed (398 cases were valid, generating 2,388 TTO evaluations)
to estimate the social preferences for derived health states. Mean age was 44.75 years (interquartile range 33.5-55.5)
and 60.1% were female. An overall algorithm for the IUI was estimated and transformed onto a dead = 0.00 and full
health = 1.00 scale. Model fits were acceptable (R-squared = 0.923 and 0.978). Predictive validity was adequate: ICC
(95% CI) = 0.928 (0.648-0.985) and Mean of Absolute Differences = 0.038.
Conclusions: The newly developed IUI is a preference-based measure for urinary problems related to NDO that
provides general population-based utility scores with adequate predictive validity.
Trial registration: ClinicalTrials.gov: NCT00461292, NCT00311376.
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Urinary problems, particularly when accompanied with
urinary incontinence (UI), have been shown to signifi-
cantly impact different domains of health-related quality
of life (HRQoL) such as emotional well-being, perfor-
mance of daily activities and social interaction [1], and
have also been associated with economic burden [2,3] and
lower productivity [1,4]. Neurogenic detrusor overactivity
(NDO) is an etiology of UI that is caused by conditions
such as multiple sclerosis (MS) or spinal cord injury (SCI).
Detrusor overactivity is an involuntary bladder contraction
during the filling phase of cystometry [5]. As a result of a
disruption in the regulation of the micturition reflex,
NDO patients frequently suffer from urinary symptoms
including urgency and urinary urgency incontinence,
which negatively affect their HRQoL [6,7].
A practical approach to evaluating the health states
derived from a disease is through administration of exis-
ting generic preference-based instruments such as the
EQ-5D [8,9], the Health Utility Index –Mark 2 or Mark
3- (HUI2 or HUI 3, respectively) [10,11] or the SF-6D
[12,13]. These instruments are suitable across patient
populations, regardless of the disease, allowing inves-
tigators to describe and compare important aspects of
HRQoL and produce preference-based or utility scores.
Although there is evidence to suggest that there is an
underlying basic construct measured by the three gen-
eric instruments, it is well established that they produce
different values and are not interchangeable [14-18].
Furthermore, there is controversy about their discrim-
inative ability and sensitivity to detect clinically important
changes in varying patient populations and consequently,
these measures may not be the best choice for certain
conditions [19], including urinary incontinence-related
problems [20-23].
There are a number of condition-specific instruments
available for patients with lower urinary tract symptoms
and UI. Some commonly-used measures in clinical trials
and outcomes research are the Overactive Bladder Ques-
tionnaire (OAB-q) [24], the King’s Health Questionnaire
(KHQ) [25] and the Incontinence Quality of Life Ques-
tionnaire (I-QOL) [26-28]. These instruments have good
psychometric properties in terms of reliability, construct
and discriminant validity, and responsiveness [6,24,27,29].
Recently, new efforts have been focused on estimating
utilities related to health states derived from these tools
by means of surveying different samples of patients or
general population from Europe and the US [30-32].
However, out of all these measures, only the I-QOL ques-
tionnaire includes a specific module for NDO patients de-
veloped from the needs-based model [26,27]. In addition,
the validity of the I-QOL has been demonstrated in pa-
tients with neurogenic urinary incontinence [6]. Conse-
quently, the overall aim of this research was to generate apreference-based measure from the I-QOL and its neuro-
genic set, the Incontinence Utility Index (IUI), by means
of surveying a representative sample of the general popu-
lation. This new instrument would represent a more com-
prehensive measure for valuing health states associated
with urinary problems from a range of different etiologies.
Methods
Overview
The I-QOL Questionnaire and Neurogenic Module
The I-QOL is a self-administered disease-specific instru-
ment comprised of 22 questions (5 point Likert scale)
addressing three main domains: Avoidance and Limiting
Behavior, Psychosocial Impact, and Social Embarrassment
[26,27]. A global scale score is obtained by summing up
the responses to all items and transforming the raw total
score to a 0–100 scale (0-worst/100-best HRQoL). As
noted before, the I-QOL was developed and validated
among patients with stress UI and overactive bladder
(OAB) [27] and has since been successfully tested on
other patient populations, such as NDO patients [6] or pa-
tients with urgency UI who had not been adequately ma-
naged with anticholinergic therapy [28]. The additional
module for patients with neurogenic bladder consists of 5
items about limiting caffeine drinks, worry about long-
term effects of catheterization, accessibility and privacy in
public toilets, bother associated with catheterizing, and
bother associated with the use of pads or diapers.
A 2-stage process was used to develop the IUI from
the I-QOL. The first stage was to use Rasch analysis and
classical psychometrical tests to derive an abbreviated
health state classification from the I-QOL and Neuro-
genic Module that is suitable for preference elicitation.
The second stage was to conduct a preference elicitation
survey to allow the estimation and validation of a multi-
attribute utility function (MAUF) for the IUI.
Deriving an abbreviated health state classification system
from the I-QOL and the neurogenic module
Multi-Attribute Utility Theory (MAUT) is an approach
that assigns utility weights to different outcomes by con-
sidering multiple attributes and the associated preferences
reported by a given population, and then combining indi-
vidual values into an overall utility measure. This process
involves specifying a particular form for the utility func-
tion and the possible preference interactions among the
attributes [10,11,33]. For MAUF estimation, it is import-
ant to include a range of aspects describing relevant con-
sequences of a given disease on patients’ lives to ensure
accuracy and sensitivity to change. The attributes should
not be too large, however, so as not to increase respon-
dents’ cognitive burden and make data collection im-
practical. The I-QOL, along with Neurogenic Module,
generates a total of 527 different health states. Hence,
Cuervo et al. Health and Quality of Life Outcomes 2014, 12:147 Page 3 of 12
http://www.hqlo.com/content/12/1/147a psychometric analysis was required to extract a mini-
mum but valid set of health states [34]. To this end, Rasch
analysis and statistics from Classical Test Theory (CTT)
were combined.
Rasch analysis is a scaling methodology that allows
the examination of the hierarchical structure, unidimen-
sionality and additivity of HRQoL measures [35]. Rasch
methods may be used to identify and select items in
an instrument that best cover the entire continuum
of the underlying construct and remove redundant items
[34,36,37]. Data dimensionality was investigated using the
approach suggested by Linacre (1998) [38] and item re-
sponses were analysed using the Partial Credit Model [35],
considering model fit, item and category locations, and
differential item functioning (DIF) regarding sex, age
group and etiology (i.e. MS or SCI). Model fit in the
range 0.5-1.5 was considered acceptable, and items with
centered locations and ordered categories as spread as
possible were preferred. DIF was considered relevant
when it was statistically significant and the difficulty
difference between groups was over 0.5 logits. Addition-
ally, an expert panel including the developer of the I-QOL
and other experts in urology and psychometrics was con-
vened to review the best items according to the results of
the analyses. Finally, internal consistency (Cronbach’s
α > 0.8), criterion validity (statistically significant diffe-
rences in HRQoL according to the reduction in the fre-
quency of UI episodes) and agreement with the original
I-QOL (Intraclass correlation coefficient –ICC- ≥0.75)
were tested to ensure that the abbreviated version met an
acceptable standard in these properties. The sample used
in this first stage has been described elsewhere [39,40].
Briefly, we pooled data from two randomized trials of ona-
botuliniumtoxinA (BOTOX®) 200U or 300U vs. placebo in
adult patients with UI due to NDO. A total of 691 patients
were enrolled in these two trials, 44.9% of whom had SCI
and 55.1% of whom had MS. The primary time point was
week 6; patients could request a second treatment after
week 12 and were followed up to week 52.Weighting the health states defined by the new
abbreviated health state classification system
Elicitation survey
A cross-sectional observational study was conducted
between October and December 2012 to survey a rep-
resentative sample (n = 442) of English-speaking, non-
institutionalized adults from the general population in
United Kingdom (UK). Participants were eligible to par-
ticipate if they were willing to complete the interview
process and to endorse their compliance with the quality
standards of the survey. Written informed consent was
obtained prior to participation. Exclusion criteria in-
cluded cognitive impairment, suspicion of being underthe effects of alcohol or narcotics use during the study
visit, and any concurrent medical condition limiting their
capacity to complete the evaluation.
Sample size was set to a minimum of 338 responders
to enable the estimation of mean values with a confi-
dence interval of ±0.032 points, and a standard deviation
of 0.3 points, assuming a normal distribution of scores
with a confidence interval of 95% (t-value = 1.96) [41].
However, given the complexity of the elicitation pro-
cess and previous experiences [42], it was estimated
that a maximum of 30% of the respondents would not
be able to successfully complete all the proposed rat-
ing exercises. Hence, a total of 440 participants were
interviewed.
Sampling was carried out in two steps: Cluster ran-
dom sampling was first applied based on UK regions/
postcodes. Subjects were then randomly selected from
each region/postcode while monitoring other key socio-
demographic variables (age, gender, education and em-
ployment status). The uniqueness of each participant’s
identity was verified at recruitment and before the in-
terview using their name and address. Single visits for
interviews were face to face and conducted using a
Computer Assisted Personal Interviewing methodology,
at either a central location in major hubs across the UK,
or by visiting respondents at home at an agreed time
and date. Respondents were offered £20 for participa-
ting in the survey, plus an additional £5 for travel ex-
penses if they were asked to come to a central location
to participate.
A total of 10 professional interviewers with required
qualifications and relevant experience in conducting face
to face interviews collaborated in this research. They re-
ceived intensive instruction, including role-playing ses-
sions to ensure the quality of interviews. Interviewers
were required to record the time needed to complete
each interview immediately following each survey, and
also to rate the degree of understanding and cooperation
from participants along with the overall quality of the
interview.
Opinion Health© was in charge of data collection which
was conducted according to the Code of Conduct of the
Market Research Society [43], European Pharmaceutical
Market Research Association [44] and qualitative recruit-
ment best practice outlined by The Association of Quali-
tative Research [45].
All procedures and materials were tested in a pilot
study (n = 13) to identify any practical problems with
data collection and to validate instruments and materials
used prior to the study. Following the pilot study, add-
itional debriefing sessions were conducted with the in-
terviewers in order to ensure that interviews would be
conducted in a systematic way to minimize possible sour-
ces of bias.
Figure 1 Presentation diagram of the time trade-off technique.
Life P= The most desirable health state/Full health/The best health
state imaginable. Life A= A given health stated derived from the
abbreviated health state classification system.
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classification system
All health states were carefully chosen to allow estima-
tion of the 5 single-attribute utility functions, each of the
attribute weights in the multi-attribute utility function,
and the interaction term (see MAUF estimation below). A
total of 16 different states were evaluated (5 single-
attributes and 11 multi-attributes).
Respondents were asked to assume a time horizon
range of 30 years to better reflect the chronic nature of
the health states presented. This period of time is close
to the average expected years of life for a middle-age
person according to UK life expectancy tables. The time
horizon and the chronicity of states were discussed with
all the participants before proceeding with the interview.
In addition to basic socio-demographic variables, each
participant responded to the following evaluation exer-
cises required for MAUF estimation:
– Visual Analogue Scale (VAS) rating of single-
attribute utility functions. For each attribute (n = 5),
VAS rating of the intermediate level was conducted
on a thermometer feeling scale anchored at 0- the
least desirable or the worst level at each attribute
and 100- the most desirable or best level at each
attribute.
– VAS rating of multi-attribute health states: A total
of 5 corner states, 3 intermediate or marker states
and 3 anchoring states were performed. Intermediate
or marker states were chosen to ensure the evalu-
ation of a wide range of levels within the 5 targeted
attributes, enhancing the precision of estimations.
Anchoring references were: 0- the least desirable
health state defined by the attributes (health state
W) or dead - and 100-the most desirable health
state or perfect health, defined as the conjunction of
the top level at each attribute (health state P) [11]. It
is important to note the lowest anchor states were
chosen depending on each participant’s preferences.
Therefore, for those respondents who declared that
being dead was preferable to health state W, being
dead was measured on a scale ranging from 0-health
state W to 1- the most desirable/perfect health scale.
In contrast, for those respondents who valued being
dead as worse than health state W, health state W
was then valued on a scale ranging from 0-dead to
1-the most desirable/perfect health scale.
– Time Trade-Off rating (TTO) for power function
estimation and for evaluation of MAUF predictive
validity. A total of 6 different states were assessed:
3 corner states and all the intermediate or marker
states previously described. During the elicitation
process, a “ping-pong” presentation was used to
converge on an indifference point between thealternatives (Figure 1). All participants were
requested to think about the differences between the
health states compared in each exercise, always
keeping in mind that all other important, broader
factors would remain constant (family, job, friends,
income, etc.) under all the presented scenarios.
MAUF estimation
A person-mean utility approach was used to estimate a
general utility function based on community responses
[10,11,42]. MAUF forms include the additive form, the
multiplicative form and the multi-linear form [10]. A
detailed introduction to the principles for MAUF estima-
tion can be found in the literature [10,11,33]. Consider-
ing the reduced version of the I-QOL comprises 5 health
domains, the multiplicative MAUF is reasonable and has
empirical support [10,33]. Since it is easier for respon-
dents to imagine corner states (with one attribute at its
worst level and the rest of attributes at their best level),
this function is normally expressed in terms of disutility
















cj is equal to the disutility of the corner state for at-
tribute j and represents the weight attached to that at-
tribute. If the sum of all cj equals 1 then the additive
model holds. c is the interaction term and results from
solving Equation 2. The methods applied in this research
are similar to those followed to develop the HUI-3 [11].
A complete description of the statistical approach can be
found in the Additional file 1. Briefly, after confirming
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split in 2 groups according to the health state they con-
sidered less preferable (dead or the worst health state
possible in the abbreviated health state classification sys-
tem). Hence, two separate power functions [46] were
calculated to convert VAS values (v) into utilities (u) and
the adjusted overall person mean scores were calculated
with utility values ranging from Dead = 0.00/P = 1.00 scale.
Next, the relative weight of each parameter (cj in disutility
terms or wj in utility terms) and its interaction form were
studied for each group and for the overall sample and fi-
nally, the IUI algorithm was estimated.
Predictive validity of the IUI
The accuracy of the algorithm was analysed by comparing
estimated and directly measured utilities (TTO) on inter-







I-QOL01 0.17 1.04 1.12
I-QOL02 −1.07 1.25 1.33
I-QOL03 −0.85 1.23 1.32
I-QOL04 0.26 1.05 1.19
I-QOL05 −0.29 0.97 1.01
I-QOL06 −0.15 0.88 0.83
I-QOL07 0.22 0.74 0.70
I-QOL08 −0.32 1.09 1.12
I-QOL09 0.51 0.75 0.74
I-QOL10 0.22 0.94 0.97
I-QOL11 0.25 0.86 0.83
I-QOL12 0.27 1.01 1.10
I-QOL13 −0.12 1.10 1.12
I-QOL14 0.44 0.72 0.68
I-QOL15 −0.29 0.92 0.92
I-QOL16 −0.46 0.82 0.81
I-QOL17 −0.12 0.75 0.72
I-QOL18 0.76 0.75 0.69
I-QOL19 0.91 0.95 0.82
I-QOL20 0.46 0.94 0.92
I-QOL21 −0.45 0.98 0.96
I-QOL22 −0.47 1.24 1.37
Neurog1† −0.26 1.20 1.29
Neurog2 −0.23 1.33 1.61
Neurog3 0.95 1.06 0.99
Neurog4 −0.51 1.56 1.85
Neurog5 0.15 1.14 1.16
*Differential Item Functioning; †Neurogenic Module of the I-QOL.– Sum of total differences (Σ differences): Σ
differences = Σ (predicted uj – observed
Person-Mean uj)
– Mean of differences (MD): MD = [Σ (predicted
uj – observed Person-Mean uj)/nj]
– Mean of absolute differences (MAD): MAD = [Σ |
(predicted uj – observed Person-Mean uj)|/nj]
– Overall standard deviation (OSD) of differences:
OSD = [(Σ (predicted uj – observed Person-
Mean uj)
2)/(nj-1)]
– ICC between estimated and directly measured
scores [47].
For these metrics, values as close to zero as possible
are preferred, except for the ICC, interpreted as any cor-
relation. The statistical packages WinSteps software ver-
sion 3.72.3 and Stata10 along with the spreadsheet Exceleasure
relation
Etiology DIF* Sex DIF
Contrast p Contrast p
0.48 0.60 0.000 −0.47 0.000
0.50 0.23 0.002 −0.29 0.000
0.51 0.59 0.000 −0.41 0.000
0.47 0.60 0.000 −0.40 0.000
0.55 −0.25 0.001 0.10 0.209
0.59 0.00 1.000 0.14 0.060
0.61 −0.04 0.595 0.00 1.000
0.51 −0.35 0.000 0.27 0.000
0.60 0.16 0.056 −0.05 0.557
0.52 0.76 0.000 −0.53 0.000
0.56 −0.21 0.013 0.19 0.029
0.49 0.18 0.025 −0.09 0.230
0.49 0.33 0.000 −0.19 0.010
0.61 0.00 1.000 −0.03 0.761
0.58 0.12 0.103 0.00 1.000
0.62 −0.06 0.432 0.00 1.000
0.63 0.00 1.000 0.00 1.000
0.57 −0.22 0.017 0.00 1.000
0.48 −0.20 0.054 0.13 0.195
0.51 −0.06 0.521 −0.08 0.376
0.57 0.13 0.075 −0.11 0.132
0.48 −0.43 0.000 0.29 0.000
0.47 0.00 1.000 0.00 1.000
0.42 −0.61 0.000 0.57 0.000
0.42 −0.24 0.025 0.18 0.099
0.39 −0.57 0.000 0.51 0.000
0.46 −0.11 0.128 −0.12 0.096
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Outputs from Rasch analysis are presented in Table 1.
No age related DIF was identified. Items 1, 3, 4 and 10
in the I-QOL and 2 and 4 in the Neurogenic Module
had etiology related DIF. Item 10 from the I-QOL and 2
and 4 from the Neurogenic Module had sex related DIF.
These six items were removed from the selection based
exclusively on the results of the Rasch analysis. Add-
itionally, as previously stated, an expert panel then pro-
ceeded to consider the results of the analysis jointly with
the item content, to reach the final selection of 5 items
considered to represent a set of complementary attri-
butes. The 5 response categories were collapsed into 3
to simplify health state valuation, yielding the abbrevia-
ted health state classification system (Table 2). This final
version proved to be internally consistent and valid for
NDO patients according to the psychometric analyses
presented in Table 3: at week 6, the abbreviated health
state classification proved to have adequate ability to de-
tect changes in those patients who showed a reduction
in incontinence episodes (responders), and the associ-
ation between daily incontinence episodes and health
state classification scores was considered adequate. Fur-
thermore, the level of agreement between the original
I-QOL and the abbreviated health classification systemTable 2 The abbreviated health state classification system de
Attributes Levels of response
I-QOL Item5: Depression I feel not at all depressed because of my
I feel somewhat depressed because of m
I feel extremely depressed because of my
I-QOL Item8: Urine Smell I do not worry at all about other people s
I worry somewhat about other people sm
I worry a very great deal about other peo
I-QOL Item13: Sleep I have no difficulty getting a good night’s
I have some difficulty getting a good nig
I have extreme difficulty getting a good n
I-QOL Item19: Bladder Control I feel I have control over my bladder
I feel I have some control over my bladde
I feel I have no control over my bladder
I-QOL Item20: Drinks I have to be not at all careful about what
incontinence
I have to be somewhat careful about wha
incontinence
I have to be extremely careful about wha
incontinence
*Summary raw score was transformed into a 0 (worst health status) – 100 (best hea
form = (the sum of the 5 items - lowest possible score)* 100/possible raw score ranwas high (ICC = 0.90; 95% CI: 0.89-0.91) and statistically
significant (p < 0.001).
Weighting the health states derived from the I-QOL
Complete descriptions of the multi-attribute health states
and the sample are presented in Tables 4 and 5. A total of
442 interviews were completed, however, 44 cases were
withdrawn because they presented at least one inconsist-
ency in their ratings: if VAS values for a given corner state
(health states A to E, Table 4) were lower than the VAS
values of comparable marker states (M1 to M3, Table 4),
n = 50 (please note some participants provided more than
one inconsistent answer); or if the value of any corner or
marker states were lower than the VAS value of the least
desirable health state, n = 24. Only those participants suc-
cessfully completing all the rating exercises were included,
n = 398, generating a total of 2,388 TTO evaluations. With
respect to interview quality, 97.7% were performed with
full cooperation of the respondent, 84.7% of participants
thought carefully before answering, and 84.9% experi-
enced very little or no problems completing the survey.
Moreover, mean time required to complete the survey was
30.2 minutes (Standard deviation -SD- 10.9) and the vast
majority of interviewers rated the quality as good or very
good (94.2%) with less than 1% of interviews being consid-
ered of inferior quality.
A majority of respondents were female (60.1%), mean
age was 44.75 years (SD14.6); 60.8% had at least a diploma
education (2 years of college) and a similar percentagerived from the I-QOL and Neurogenic Module
Score*
urinary problems or incontinence 5
y urinary problems or incontinence 3
urinary problems or incontinence 1
melling urine on me 5
elling urine on me 3
ple smelling urine on me 1
sleep because of my urinary problems or incontinence 5
ht’s sleep because of my urinary problems or incontinence 3




or how much I drink because of my urinary problems or 5
t or how much I drink because of my urinary problems or 3
t or how much I drink because of my urinary problems or 1
lth status) scale with the following algorithm: Scale score of the abbreviated
ge.
Table 3 Psychometric properties of the abbreviated health state classification system in neurogenic detrusor
overactivity patients
Psychometric properties*
Criterion validity: differences in the scale score of the abbreviated health state classification system (0: worst health status – 100: best
health status) according to the reduction in the frequency of urinary incontinence episodes at week 6)
N Mean 95% CI Lower L. 95% CI Upper L. p
Scale score at Day 1 Reduction <50% 225 35.11 32.73 37.49 0.242
50% < = Reduction <100% 224 35.04 32.75 37.34
100% Reduction 188 37.93 35.40 40.45
Scale score at Week 6 Reduction <50% 222 38.69 36.14 41.25 <0.001
50% < = Reduction <100% 224 54.33 54.62 57.04
100% Reduction 186 70.81 67.72 73.89
Convergent validity Spearman correlation coefficient
Daily Incontinence episodes
Scale score at Day 1 −0.22 <0.01
Scale score at Week 6 −0.43
*Overall internal consistency of the abbreviated health state classification system was adequate (Cronbach’s α = 0.814). Regarding construct validity, Principal
Component analysis highlighted one principal component (57.5% of explained variance. All the items were highly correlated with that component rxy ≥ 0.73).
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tus, 31.7% reported a chronic illness and 8.8% an acute
disease. Regarding previous experience, 36.4% declared
they had suffered symptoms associated with OAB or UUI
and 48.0% recognized some of these problems in their rel-
atives or friends.
With respect to participants’ preferences about the
worst state described by the abbreviated health state
classification system and dead, most of them (n = 294,









A† 3 1 1 1 1
B 1 3 1 1 1
C† 1 1 3 1 1
D† 1 1 1 3 1
E 1 1 1 1 3
M1† 1 2 3 1 2
M2† 3 1 1 2 2
M3† 1 2 1 3 3
P 1 1 1 1 1
W 3 3 3 3 3
Dead – – – – –
*Levels of all attributes were coded as follows: 1-best possible level,
2-intermediate level and 3-worst possible level. All health states were rated
with a visual analogue scale (0–100). A, B, C, D, E: corner states. M1, M2, M3:
intermediate/marker states. P: Best health state possible. W: Worst health
state possible.
†Health states also evaluated with a time trade-off technique.in health state W (Group B), while the rest (n = 104,
26.1%) preferred being dead to living in health state W
(Group A).
MAUF estimation and final algorithm of the Incontinence
Utility Index
Trimmed values (10%) were fitted separately for each
group based on power functions (Equation 3 in Additional
file 1) and natural log transformations (Equation 4 in
Additional file 1) to convert mean VAS (v) into utility
scores (u). Regression models yielded good fit (R2 group
A = 0.923 and R2 group B = 0.978) and power functions
resulted as follows: Group A, u = 1-(1-v)1.229 and Group B,
u = 1-(1-v)0.841. Estimates of the relative weight of each at-
tribute fitted in the perfect health = 0 and worst state = 1
for Group A were: c1 = 0.393, c2 = 0.450, c3 = 0.387, c4 =
0.562 and c5 = 0.283 (Σcj = 2.076; c = −0.911). For Group
B: c1 = 0.636, c2 = 0.640, c3 = 0.616, c4 = 0.775 and c5 =
0.490 (Σcj = 3.158; c = −0.994). From these results it was
seen that the multiplicative form was an appropriate form.
Final utilities were calculated based on the prevalence
proportion in Person-Mean A and Person-Mean B groups
(both in W= 0.00/P = 1.00 scale): uj = (104* Person-Mean
A uj + 294 * Person-Mean B uj -re-scaled-)/398. A positive
linear transformation was applied to re-scale the utilities
into a dead = 0.00 / P = 1.00 scale to facilitate comparisons
with other utility measures. Table 6 shows utility weights
estimated for the multi-attribute health states defined
in Table 4. The disutility weights estimated for each at-
tribute from the overall sample were: c1 = 0.470, c2 =
0.484, c3 = 0.456, c4 = 0.590 and c5 = 0.358 (Σcj = 2.357;
c = −0.951). Once again the results rejected the linear ad-
ditive form and showed that all attributes were preference
Table 5 Description of participants in the elicitation
survey (valid cases, n= 398)
Variable n %
Gender Female 239 60.1
Region North East 20 5.0
North West 38 9.5
Yorkshire and The Humber 35 8.8
Midlands 55 13.8
East of England 32 8.0
London 47 11.8
South East 68 17.1
South West 37 9.3
Scotland 36 9.0
Northern Ireland 10 2.5
Wales 20 5.0
Education Some secondary school 14 3.5
GCSE or equivalent 71 17.8
‘A’ level or equivalent 71 17.8
Diploma or certificate of higher
education
66 16.6
Bachelor’s degree or equivalent 107 26.9
Master’s or Doctoral degree/
Post graduate certificate
69 17.3
Employment status Working full-time 150 37.7
Working part-time 56 14.1
Not working 55 13.8
Looking for work 4 1.0
Student 36 9.0
Retired 65 16.3
Self employed 32 8.0
Age Mean (SD) 44.75 14.6









Acute disease Yes 35 8.8




Table 6 Estimated overall utility scores
Health state n u* u’†
A 398 0.427 0.530
B 398 0.409 0.516
C 398 0.444 0.544
D 398 0.280 0.410
E 398 0.564 0.642
M1 398 0.259 0.392
M2 398 0.243 0.379
M3 398 0.185 0.331
P 398 1 1
D 398 −0.219 0
W 398 −0.037 0.150
*u = (104* Person-Mean A uj + 294. *Person-Mean B uj -re-scaled-)/398.
†Positive linearly transformed into a dead = 0.00/P = 1.00 scale.
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and the overall MAUF are presented in Table 7 with pos-
sible scores ranging from 0.036 (worst health state) to 1
(perfect health).Predictive validity of the MAUF
Mean utility scores of marker states directly elicited on
the TTO were compared against those estimated by the
MAUF to test its predictive validity. The results were as
follows: Σ differences = −0.038; MD = −0.013; MAD =
0.038; OSD = 0.004 and ICC (95% CI) = 0.928 (0.648-
0.985). Thus, the calculated MAUF showed a very slight
tendency to underpredict directly elicited utilities. More-
over, the level of agreement found between both me-
thods (ICC) was good and only 7.2% of variability could
not be attributed to subjects.
Discussion
In this study, a new utility index, the IUI, has been esti-
mated from the abbreviated health state classification
system derived from I-QOL and its neurogenic module
by means of eliciting preferences from a representative
sample of UK adult general population [50]. The abbre-
viated I-QOL version was internally consistent and able
to capture clinically important differences in clinical sta-
tus of NDO patients with UI (i.e. changes in HRQoL
according to reductions in the average number of IU ep-
isodes per week). Furthermore, a high level of agreement
was found between the reduced version and the original
I-QOL, confirming the appropriateness of the abbrevi-
ated health state classification system of 5 domains and
its modelling space for utility estimation. Moreover, all
the psychometric procedures undertaken to reduce the
I-QOL have been successfully applied previously [30,36,51]
and have been recently recommended [34].
Regarding the elicitation process, methods applied are
consistent with those used to develop one of the most
widespread and robust generic utility measures, the HUI
[10,11]. As has occurred in previous publications, the
additive model was rejected in this study [10,11,42] and
attributes were preference complements: for instance,
Table 7 Single and Multi-attribute utilities
Single-attribute utility scores
Level Depression Urine Smell Sleep Bladder Control Drinks
1 1.00 1.00 1.00 1.00 1.00
2 0.600 0.457 0.613 0.627 0.655
3 0.178 −0.034 0.178 0.178 0.178
Final Multi-attribute utility function coefficients (p = 0.051)
Level Depression (w1) Urine Smell (w2) Sleep (w3) Bladder Control (w4) Drinks (w5)
1 1.00 1.00 1.00 1.00 1.00
2 0.821 0.750 0.832 0.791 0.883
3 0.633 0.524 0.644 0.539 0.721
Final algorithm: u* = 1.051 (w1 * w2 * w3 * w4 * w5) – 0.051
*u is the utility of a health state (number of possible health states = 243). Dead = 0.0 and Perfect Health = 1.0.
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and not having bladder control is greater than the separate
effect of being depressed and not having bladder control,
but smaller than the sum of these two problems.
In addition, predictive validity of IUI scoring algorithm
was confirmed after comparing the direct utility values
and those estimated for the final algorithm. Recogniz-
ing that IUI algorithm showed a slight tendency to
underpredict the directly elicited utilities, error size was
small and comparable to those errors reported for other
utility instruments [11]. What is more, the ICC between
direct and indirect values showed an adequate level of
agreement.
Generic preference-based indices have historically been
the most commonly used means of estimating utilities
across a variety of conditions. However, substantial re-
search has been conducted which shows the limitations of
these instruments in different conditions [19-22], as well
as the lack of concordance between the utility values
obtained from their application [14-16,18,52,53]. As a
result, the development of condition-specific preference-
based measures has been gaining ground in recent years
[30-32,54].
There are published studies focused on obtaining utility
scores from condition-specific instruments for urinary
problems. An algorithm has been generated to derive util-
ities from the KHQ by eliciting preferences from a sample
of UI patients [31]. Kay et al. (2013) [32] mapped EQ-5D
utility scores from the I-QOL among patients with neuro-
genic and idiopathic OAB using cross-sectional data from
Europe and the US. Finally, Yang et al. estimated a popula-
tion’s preference-based index from the OAB-q, the OAB-
5D [30]. Consequently, although the IUI was derived from
the I-QOL and its specific module for neurogenic pa-
tients, the OAB-5D is the most similar instrument be-
cause its modelling space was also obtained from applying
Rasch, preference elicitation involved TTO evaluations,
and also incorporates general population preferences.Nevertheless, relevant differences lay in the characteristics
of the samples used in the reduction process (we specific-
ally used NDO patients) and in the estimation models ap-
plied to derive the utility scores since OAB-5D followed
the methods described previously for the SF-6D [12] and
we computed a MAUF in accordance with the HUI latest
versions [10,11]. Despite these differences, mean abso-
lute error/differences in both measures are comparable
(OAB-5D: 0.044 versus IUI: 0.038). Hence, additional re-
search is needed to compare performance of each respect-
ive measure in the same populations (i.e. criterion validity,
responsiveness and influence on cost-effectiveness ratios).
Despite the fact that the MAUF has proven robust,
there are a number of limitations in this research. It
should be noted that we used TTO evaluations instead
of the Standard Gamble (SG). Although SG is considered
the preferred technique to collect subjects’ preferences,
TTO is a legitimate and extensively used technique,
generally considered easier to understand and less time
consuming [30,55]. Preferences were elicited from a UK-
specific population, so caution should be used before ap-
plying the algorithm to other countries, especially if the
population is expected to perceive urinary problems dif-
ferently. Additionally, as a condition-specific preference-
based measure, the IUI may suffer from some potential
risks in terms of comparability of results [34]. The risk of
focusing effects (i.e. cognitive bias that occurs when partici-
pants place too much importance on the problems associ-
ated with the health states presented to them compared
with other conditions) was obviated as best as possible by
clearly stating throughout the preference elicitation pro-
cess that, apart from the health states described by the re-
duced version of the I-QOL, other important aspects of
life (i.e. family, economic situation, friends, job, etc.)
would remain constant.
Another source of limitations referred to as anchoring
(defining a specific upper anchor that could make com-
parability across other preference-based instruments
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upper limits during the evaluation process were defined as
the most desirable health state, the best health state im-
aginable, or full health to best facilitate comparisons with
other scales. Finally, while the 30-year time horizon was
set to illustrate the chronicity of health states, this time
frame may not have been the most appropriate for partici-
pants under 30 years of age (18.3%) or, particularly for
those older than 60 years (17.6%). Thus, this time horizon
may result in some over/underestimations during TTO
exercises with these subsamples [56,57].Conclusions
The I-QOL and the IUI are valid-in-population mea-
sures for measuring HRQoL and utilities, respectively,
associated with urinary problems. Although the IUI is
the first utility measure that has been developed for a
specific subset of patients with urinary symptoms (NDO
population), it is important to note that the final se-
lection of attributes included in the IUI is from the origi-
nal I-QOL, with no items utilized from the Neurogenic
Module. Hence, investigators may test its applicability in
other relevant subsamples. It is worth noting that the
use of a representative sample of general population to
value its health states may ease the application of this in-
strument in new subsets of patients suffering from uri-
nary problems. New research is currently underway to
confirm the soundness of the IUI modelling space on
idiopathic OAB patients and to study the responsiveness
and the minimally important differences of the IUI in
both NDO and idiopathic OAB populations. These in-
sights will be of value to future researchers using the IUI
instrument which is intended to complement utility
estimates provided by generic instruments to support
decision-making with reliable, valid and understand-
able information presented on a similar scale.Additional file
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